Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06002945 · ClinicalTrials.gov registry record
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
A clinical trial of Myasthenia Gravis, sponsored by Yale University.
- Active
- Registry status
- 400
- Enrollment target
- 10
- Study locations
NCT06002945: Active study of Myasthenia Gravis, sponsored by Yale University.
NCT06002945 is a study of Myasthenia Gravis that is active but no longer recruiting, run by Yale University. The registered enrollment target is 400 participants, above the 179-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (123% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06002945, a study of Myasthenia Gravis, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.
Conditions Studied
Interventions
- OTHER Blood sample
Study Locations (10)
North Carolina
- University of North Carolina - Chapel Hill
- Duke University Medical Center - Durham
- Wake Forest University - Winston-Salem
California
- University of California-Irvine - Irvine
- Cedars Sinai Medical Center - Los Angeles
Connecticut
- Yale University - New Haven
District of Columbia
- George Washington University - Washington D.C.
Illinois
- University of Chicago - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2026-12 |
What the registry record for NCT06002945 still lists
NCT06002945 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (123% higher).
The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Blood sample is the first listed.
NCT06002945 lists 10 locations in 7 states (North Carolina, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06002945 about?
NCT06002945 is a clinical study titled "Exploring Outcomes and Characteristics of Myasthenia Gravis 2". The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.
What is the current status of trial NCT06002945?
This trial is currently active not recruiting. The enrollment target is 400 participants. The study started on 2021-01-12. Estimated completion is 2026-12.
What conditions does trial NCT06002945 study?
This clinical trial studies the following conditions: Myasthenia Gravis.
What interventions are being tested in trial NCT06002945?
The interventions under investigation include: Blood sample (OTHER).
Who is sponsoring clinical trial NCT06002945?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06002945 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06002945's enrollment target sits among peer trials
400 5th of 32 higher than 28 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
RECRUITING
-
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RECRUITING · Phase 3
-
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RECRUITING
-
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI